ERBB receptor regulation of ESX/ELF3 promotes invasion in breast epithelial cells

Open Cancer Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 89-100

  Coppe, Jean Philippe ^c   Amend, Clifton ^b   Semeiks, Jeremy ^c   Baehner, Frederick L ^a   Bayani, Nora ^c   Campisi, Judith ^b,c   Benz, Christopher C ^a,b   Gray, Joe W ^a,c   Neve, Richard M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Breast cancer; Elf3; Epithelial; Erbb2; Esx

Indexed keywords

4 HYDROXYTAMOXIFEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL RESTRICTED WITH SERINE BOX PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 78249269486     PISSN: None     EISSN: 18740790     Source Type: Journal    
DOI: 10.2174/1874079001003010089     Document Type: Article

References (52)

1. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827-837.
2. Andreoli JM, Jang SI, Chung E, Coticchia CM, Steinert PM, Markova NG. The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. Nucleic Acids Res 1997; 25: 4287-4295.
3. Brembeck FH, Opitz OG, Libermann TA, Rustgi AK. Dual function of the epithelial specific ets transcription factor, ELF3, in modulating differentiation. Oncogene 2000; 19: 1941-1949.
4. Chang CH, Scott GK, Baldwin MA, Benz CC. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP). Oncogene 1999; 18: 3682-3695.
5. Neve R, Chang CH, Scott GK, et al. The epithelium-specific ets transcription factor ESX is associated with mammary gland development and involution. FASEB J 1998; 12: 1541-15450.
6. Oettgen P, Alani RM, Barcinski MA, et al. Isolation and charac-terization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol Cell Biol 1997; 17: 4419-4433.
7. Yoshida N, Yoshida S, Araie M, Handa H, Nabeshima Y. Ets family transcription factor ESE-1 is expressed in corneal epithelial cells and is involved in their differentiation. Mech Dev 2000; 97: 27-34.
8. Tymms MJ, Ng AY, Thomas RS, et al. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene 1997; 15: 2449-2462.
9. Choi SG, Yi Y, Kim YS, et al. A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor. J Biol Chem 1998; 273: 110-117.
10. Oettgen P, Kas K, Dube A, et al. Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes. J Biol Chem 1999; 274: 29439-29452.
11. Reddy SP, Vuong H, Adiseshaiah P. Interplay between proximal and distal promoter elements is required for squamous differentiation marker induction in the bronchial epithelium: role for ESE-1, Sp1, and AP-1 proteins. J Biol Chem 2003; 278: 21378-21387.
12. Kwon JH, Keates S, Simeonidis S, Grall F, Libermann TA, Keates AC. ESE-1, an enterocyte-specific Ets transcription factor, regulates MIP-3alpha gene expression in Caco-2 human colonic epithelial cells. J Biol Chem 2003; 278: 875-884.
13. Rudders S, Gaspar J, Madore R, et al. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene. J Biol Chem 2001; 276: 3302-3309.
14. Eckel KL, Tentler JJ, Cappetta GJ, Diamond SE, Gutierrez-Hartmann A. The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. DNA Cell Biol 2003; 22: 79-94.
15. Mysorekar IU, Mulvey MA, Hultgren SJ, Gordon JI. Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J Biol Chem 2002; 277: 7412-7419.
16. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
17. Chang CH, Scott GK, Kuo WL, et al. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene 1997; 14: 1617-1622.
18. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.
19. Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY. Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res 2004; 10: 2044-2051.
20. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
21. [21] Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.
22. Metzger D, Clifford J, Chiba H, Chambon P. Conditional Site-Specific Recombination in Mammalian Cells Using a Ligand-Dependent Chimeric Cre Recombinase. Proc Natl Acad Sci USA 1995; 92: 6991-695.
23. Neve RM, Ylstra B, Chang CH, Albertson DG, Benz CC. ErbB2 activation of ESX gene expression. Oncogene 2002; 21: 3934-3938.
24. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
25. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649-657.
26. Bargmann CI, Weinberg RA. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 1988; 85: 5394-5398.
27. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1: 46-54.
28. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
29. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999; 274: 8865-8874.
30. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005; 21: 2067-2075.
31. Brown C, Gaspar J, Pettit A, et al. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem 2004; 279: 12794-12803.
32. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-279.
33. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
34. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003; 22: 145-52.
35. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16: 79-87.
36. McGuire JK, Li Q, Parks WC. Matrilysin (Matrix Metalloproteinase-7) Mediates E-Cadherin Ectodomain Shedding in Injured Lung Epithelium. Am J Pathol 2003; 162: 1831-1843.
37. Le TL, Yap AS, Stow JL. Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. J Cell Biol 1999; 146: 219-232.
38. El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem 2004; 279: 20794-20806.
39. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metallo-proteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28261-28267.
40. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001; 3: 459-468.
41. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-611.
42. Lynch CC, Crawford HC, Matrisian LM, McDonnell S. Epidermal growth factor upregulates matrix metalloproteinase-7 expression through activation of PEA3 transcription factors. Int J Oncol 2004; 24: 1565-1572.
43. Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219-226.
44. Schedin PJ, Eckel-Mahan KL, McDaniel SM, et al. ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene 2004; 23: 1766-1779.
45. Prescott JD, Koto KS, Singh M, Gutierrez-Hartmann A. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol 2004; 24: 5548-5564.
46. Blick T, Widodo E, Hugo H, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008; 25: 629-642.
47. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155-166.
48. +, K(+)-ATPase and E-cadherin. J Cell Sci 1994; 107: 3315-3324.
49. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930-935.
50. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
51. Crawford HC, Fingleton B, Gustavson MD, et al. The PEA3 subfamily of Ets transcription factors synergizes with beta- catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001; 21: 1370-1383.
52. Trost TM, Lausch EU, Fees SA, et al. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res 2005; 65: 840-849.